Corvus Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 25, 2025

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)



· · Year Ended December 31,
· 2024 · 2023 · 2022
Operating expenses: · · · ·
Research and development	$19,385	$16,526	$24,468
General and administrative	8,163	6,881	8,097
Total operating expenses	27,548	23,407	32,565
Loss from operations	(27,548)	(23,407)	(32,565)
Interest income and other expense, net	1,824	1,584	654
Gain from sale of property and equipment	5	—	22
Change in fair value of warrant liability	(33,377)	—	—
Sublease income - related party	—	78	587
Loss before equity method investment	(59,096)	(21,745)	(31,302)
Loss from equity method investment	(3,197)	(5,284)	(10,005)
Net loss	$(62,293)	$(27,029)	$(41,307)
Net loss per share, basic and diluted	$(1.02)	$(0.56)	$(0.89)
Shares used to compute net loss per share, basic and diluted	60,985,165	48,025,274	46,553,511
Other comprehensive loss:
Unrealized gain on marketable securities	65	66	(48)
Cumulative foreign currency translation adjustment	(386)	(470)	(2,384)
Comprehensive loss	$(62,614)	$(27,433)	$(43,739)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.